Medtronic
Medtronic plc (NYSE: MDT) develops, manufactures, and sells medical devices and therapies for healthcare systems, physicians, clinicians, and patients in more than 150 countries. Its products address cardiovascular conditions, neurological and spinal disorders, surgical needs, and acute care, including pacemakers,… From the company’s description.
In fiscal 2026, Medtronic reported revenue of $36.36B, up 8.4% from fiscal 2025, and net income of $4.84B. Its operating margin was 17.8%, and operations generated $7.33B in cash. Over the twelve months to Jul 31, 2026, revenue was $37.54B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Medtronic does
In the company’s own words
Medtronic plc (NYSE: MDT) develops, manufactures, and sells medical devices and therapies for healthcare systems, physicians, clinicians, and patients in more than 150 countries. Its products address cardiovascular conditions, neurological and spinal disorders, surgical needs, and acute care, including pacemakers, heart valves, neurostimulation systems, surgical instruments, patient monitors, and endoscopy technologies. Medtronic reports three segments: Cardiovascular, Neuroscience, and Medical Surgical. Cardiovascular covers heart rhythm, structural heart, coronary, and peripheral vascular therapies; Neuroscience includes cranial and spinal technologies, specialty therapies, and neuromodulation; Medical Surgical includes surgical and endoscopy products and acute care and monitoring. Its products are sold through direct representatives and third parties, primarily to hospitals, ambulatory surgery centers, physician offices, and other healthcare providers. The Diabetes Business, which makes insulin pumps, continuous glucose monitoring systems, and related supplies, completed an initial public offering in March 2026 and was no longer a reportable segment in the fourth quarter. Medtronic had more than 95,000 full-time employees in fiscal 2026.
Company details
- Sector
- Health Care
- Industry (SIC)
- Electromedical Apparatus
- Headquarters
- GALWAY
- Fiscal year end
- April
- CIK
- 1613103
- SIC
- 3845
Financial performance, year by year
Fiscal 2015–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Medtronic — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Medtronic · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Medtronic’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Medtronic and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Medtronic's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Medtronic's last four quarterly filings that the numbers alone won't show?”